McCormick Backs 2 KRAS Drug Combinations to Extend Cancer Responses
Updated
Updated · Cancer Network · Jul 30
McCormick Backs 2 KRAS Drug Combinations to Extend Cancer Responses
1 articles · Updated · Cancer Network · Jul 30
Summary
Frank McCormick said pairing KRAS inhibitors with PI3K pathway drugs and Checkpoint inhibitors offers the clearest route to more durable responses as KRAS therapies expand in pancreatic, lung and colorectal cancers.
Single-agent KRAS blockade can trigger compensatory survival signaling, and McCormick said PI3K inhibitors could blunt that rebound and make the initial antitumor hit more effective.
Checkpoint combinations may be especially promising because KRAS helps tumors evade immune detection; suppressing KRAS could make cancer cells more visible and improve response to immunotherapy.
Early-phase trials are already testing these pairings across tumor types and treatment lines, with McCormick highlighting immune-engaging combinations in lung cancer as a likely frontline direction.
Why are KRAS inhibitors increasingly paired with PI3K drugs or immunotherapy, and which combination could finally deliver durable responses in pancreatic, lung, and colorectal cancers?
If KRAS blockade triggers multiple escape routes, are the winning combinations EGFR, PI3K, TBK1, statins, or checkpoint inhibitors—and how should doctors choose?